Genmab and AbbVie Clarify EPCORE DLBCL-1 Phase 3 Results
COPENHAGEN, Denmark and NORTH CHICAGO, Ill., July 23, 2026 Genmab and AbbVie have issued a clarification regarding the Phase...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
COPENHAGEN, Denmark and NORTH CHICAGO, Ill., July 23, 2026 Genmab and AbbVie have issued a clarification regarding the Phase...
COPENHAGEN, Denmark, June 29, 2026 Genmab A/S announced positive topline results from the Phase 3 EPCORE DLBCL-4 clinical trial...
LAUSANNE, Switzerland, June 30, 2026 ADC Therapeutics SA has announced the successful completion of patient enrollment in the LOTIS-7...
WILMINGTON, Del., June 20, 2026 Incyte Biosciences Japan G.K. has announced that Japan’s Ministry of Health, Labour and Welfare...
BASEL, Switzerland, June 18, 2026 Roche announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental...
